Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$65.68 USD

65.68
3,456,884

-1.42 (-2.12%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (59 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Chimera Investment (CIM) Q4 Earnings and Revenues Top Estimates

Chimera (CIM) delivered earnings and revenue surprises of 25.49% and 20.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) to Report Q3 Earnings: What's in Store?

In the fiscal third quarter, Medtronic (MDT) is expected to have registered strong growth for TAVR across the United States, courtesy of its higher adoption by the low-risk patient population.

Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?

Expanded claims volume and better purchasing economics are expected to have aided CVS Health's (CVS) top line in Q4.

Ecolab's Eco-Flex Teat Dip to Boost Food & Beverage Segment

The Eco-Flex Teat Dip launch is likely to expand Ecolab's (ECL) Food & Beverage product portfolio.

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

DexCom's (DXCM) fourth-quarter earnings are likely to reflect top-line growth and rising global awareness of the company's real-time CGM.

Cannabis Therapy to Drive Canopy Growth's (CGC) Q3 Earnings

Key acquisitions are expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal third quarter

What's in the Cards for DaVita (DVA) This Earnings Season?

DaVita (DVA) expects to have gained from calcimimetics in the fourth quarter.

DexCom (DXCM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?

Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.

BD Life Sciences to Aid Becton, Dickinson (BDX) Q1 Earnings

BD's (BDX) core Life Sciences arm is expected to have driven first-quarter performance.

DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know

DexCom (DXCM) closed at $237.09 in the latest trading session, marking a -1.52% move from the prior day.

Neena Mishra headshot

Best Thematic ETFs for 2020: Cloud, Internet of Things & More

Find out more about cloud computing, Internet of Things, video games and infrastructure ETFs.

ABIOMED (ABMD) to Report Q3 Earnings: What's in the Offing?

Flagship Impella likely to have boosted ABIOMED's (ABMD) fiscal Q3 earnings.

Edwards Lifesciences (EW) Q4 Earnings Lag, Sales Top Estimates

Edwards Lifesciences (EW) witnesses growth in TAVR procedures, led by strong therapy adoption across all geographies, particularly in the United States.

ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand

ResMed (RMD) exhibits robust growth in the second quarter of fiscal 2020, fueled by the strong performance of both its segment.

IDEXX (IDXX) Q4 Earnings Top Estimates, Revenues Grow Y/Y

The year-over-year upside in IDEXX's (IDXX) revenues was primarily driven by strong global gains in CAG Diagnostics' recurring revenues.

CONMED (CNMD) Earnings and Revenues Beat Estimates in Q4

CONMED's (CNMD) fourth-quarter earnings gain from higher revenues and strong performance in General Surgery segment. However, high long-term debt remains a concern.

What's in Store for Cardinal Health's (CAH) Q2 Earnings?

Cardinal Health (CAH) fiscal second-quarter earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.

Quest Diagnostics (DGX) Q4 Earnings Beat, Margins Strong

We are upbeat about Quest Diagnostics' (DGX) expanded network access, which assists the company to expedite volume growth in Q4.

Hologic (HOLX) Q1 Earnings Meet, Revenues Beat Estimates

Hologic (HOLX) exhibits robust growth in first-quarter fiscal 2020, fueled by strong performance in the majority of its segments.

Illumina (ILMN) Q4 Earnings Beat Estimates, Margins Expand

Illumina (ILMN) exhibits robust growth in the fourth quarter of fiscal 2019, fueled by strong performance of the sequencing consumable segment.

Thermo Fisher (TMO) Q4 Earnings Top, Organic Growth Solid

We are upbeat that two of Thermo Fisher's (TMO) four business segments deliver strong year-over-year revenue growth in Q4.

AmerisourceBergen (ABC) Q1 Earnings Beat, Revenues Miss

AmerisourceBergen's (ABC) Q1 earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.

Cerner (CERN) to Report Q4 Earnings: What's in the Cards?

Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to have aided Cerner's (CERN) Q4 earnings. However, contraction in gross margin is likely to have been a dampener.

McKesson (MCK) to Report Q3 Earnings: What's in the Offing?

McKesson's (MCK) core U.S. Pharmaceutical and Specialty Solutions unit is expected to reflect in fiscal Q3 results.